person · Reporting owner

Manning Paul B

Disclosed activity across 8 companies

Tapewire entity: 33957
SEC CIK: 0001494695

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Candel Therapeutics, Inc.CADL · Entity 4969	Director	September 30, 2026	October 02, 2026
Liquidia CorpLQDA · Entity 1860	Director	June 16, 2026	June 18, 2026
Pasithea Therapeutics Corp.KTTA · Entity 7685	10% owner	October 22, 2022	February 14, 2023
Verrica Pharmaceuticals Inc.VRCA · Entity 6823	Director · 10% owner	November 25, 2025	November 26, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Candel Therapeutics, Inc.

Report date September 30, 2026 · Filed October 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2036-09-30	Direct	2,189	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 2,189 · Balance 2,189 F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Liquidia Corp

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	475,465	Reported balance After 2026-06-16 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 5,882 · Balance 475,465 F1: Represents restricted stock units ("RSUs"). The RSUs convert into common stock on a one-for-one basis and shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.
Common StockSEC Table I · non-derivative	Direct	3,131,794	Reported balance Holding disclosure · report date 2026-06-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,131,794 F2: The shares are held by Reporting Person jointly with his spouse.
Common StockSEC Table I · non-derivative	IndirectSee footnote	716,311	Reported balance Holding disclosure · report date 2026-06-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 716,311 F3: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	798,335	Reported balance Holding disclosure · report date 2026-06-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 798,335 F4: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	435,674	Reported balance Holding disclosure · report date 2026-06-16 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 435,674 F5: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM.
Common StockSEC Table I · non-derivative	IndirectSee footnote	198,413	Reported balance Holding disclosure · report date 2026-06-16 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 198,413 F6: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily, the manager of PD, and has shared voting and investment power with respect to the shares held by PD.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs"). The RSUs convert into common stock on a one-for-one basis and shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.

F2: The shares are held by Reporting Person jointly with his spouse.

F3: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

F4: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust.

F5: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM.

F6: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily, the manager of PD, and has shared voting and investment power with respect to the shares held by PD.

Pasithea Therapeutics Corp.

Report date October 22, 2022 · Filed February 14, 2023

Jointly reported with PD Joint Holdings, LLC Series 2016-A, Manning Bradford, Tiger Lily Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,608,696	Reported balance Holding disclosure · report date 2022-10-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,608,696
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-06-21	Direct	Not disclosed	Reported balance Holding disclosure · report date 2022-10-22 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed

Verrica Pharmaceuticals Inc.

Report date November 25, 2025 · Filed November 26, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,958,189	Reported balance After 2025-11-25 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-11-25 · Purchase · Acquired 1,375,380 · Balance 3,958,189 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F2: The shares are held by Mr. Manning jointly with his spouse.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,348,372	Reported balance After 2025-11-25 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2025-11-25 · Purchase · Acquired 2,750,762 · Balance 3,348,372 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	25,663	Reported balance Holding disclosure · report date 2025-11-25 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 25,663 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F6: The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.
Series C Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2030-11-25	Direct	343,845	Reported balance After 2025-11-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-11-25 · Purchase · Acquired 343,845 · Balance 343,845 F8: The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F7: Immediately exercisable. F2: The shares are held by Mr. Manning jointly with his spouse.
Series C Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2030-11-25	IndirectSee footnote	687,690	Reported balance After 2025-11-25 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-11-25 · Purchase · Acquired 687,690 · Balance 687,690 F9: The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F7: Immediately exercisable. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	332,433	Reported balance Holding disclosure · report date 2025-11-25 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 332,433 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F5: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

F2: The shares are held by Mr. Manning jointly with his spouse.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.

F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F5: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

F6: The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.

F7: Immediately exercisable.

F8: The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

F9: The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Acumen Pharmaceuticals, Inc.

Report date July 06, 2021 · Filed July 08, 2021

Section 16 reporting ended · disclosed 2021-07-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,040,193	Reported balance After 2021-07-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-07-06 · Conversion · Acquired 2,950,484 · Balance 3,040,193 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,352,693	Reported balance After 2021-07-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-07-06 · Purchase · Acquired 312,500 · Balance 3,352,693 F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	657,985	Reported balance After 2021-07-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-07-06 · Conversion · Acquired 657,985 · Balance 657,985 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-06 · Conversion · Disposed 1,634,515 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-06 · Conversion · Disposed 1,315,969 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-06 · Conversion · Disposed 657,985 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

Filing footnotes · ownership attribution and instrument terms

F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

AveXis, Inc.

Report date May 15, 2018 · Filed May 15, 2018

Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-05-15 transaction · row 1 1 source row Row 1 · 2018-05-15 · Disposition to issuer · Disposed 228,752 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Includes 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
Common StockSEC Table I · non-derivative	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-05-15 · Disposition to issuer · Disposed 1,201,160 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: These shares are held by PBM Capital Investments, LLC ("PBM"). The Reporting Person has the sole voting and investment power with respect to the shares held by the PBM. The Reporting Person disclaims beneficial ownership of the shares held by PBM except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2018-05-15 · Disposition to issuer · Disposed 25,293 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F4: These shares are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2026-02-10	Direct	Reported balance After 2018-05-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-05-15 · Disposition to issuer · Disposed 26,496 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.25 · Expires 2027-05-30	Direct	Reported balance After 2018-05-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-05-15 · Disposition to issuer · Disposed 2,454 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13	Direct	Reported balance After 2018-05-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-05-15 · Disposition to issuer · Disposed 2,905 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2025-05-04	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-05-15 · Disposition to issuer · Disposed 137,154 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F6: In connection with the transactions contemplated by the Merger Agreement, the Warrant was canceled in exchange for a lump sum cash payment equal to (i) the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by (ii) the number of shares of Common Stock underlying the Warrant. F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2024-03-07	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-05-15 · Disposition to issuer · Disposed 103,478 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F8: The amount reported reflects a pro rata distribution to members of PBM on August 15, 2016. In prior reports, the Reporting Person reported beneficial ownership of 130,623 shares of common stock underlying the Warrant. F9: Immediately exercisable. F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.

F2: Includes 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.

F3: These shares are held by PBM Capital Investments, LLC ("PBM"). The Reporting Person has the sole voting and investment power with respect to the shares held by the PBM. The Reporting Person disclaims beneficial ownership of the shares held by PBM except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F4: These shares are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.

F6: In connection with the transactions contemplated by the Merger Agreement, the Warrant was canceled in exchange for a lump sum cash payment equal to (i) the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by (ii) the number of shares of Common Stock underlying the Warrant.

F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F8: The amount reported reflects a pro rata distribution to members of PBM on August 15, 2016. In prior reports, the Reporting Person reported beneficial ownership of 130,623 shares of common stock underlying the Warrant.

F9: Immediately exercisable.

Dova Pharmaceuticals Inc.

Report date November 12, 2019 · Filed November 12, 2019

Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-12 transaction · row 1 1 source row Row 1 · 2019-11-12 · Other · Disposed 12,979,016 · Balance 0 F1: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship.
Common StockSEC Table I · non-derivative	IndirectBy LLC	0	Reported balance After 2019-11-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-11-12 · Other · Disposed 1,783,226 · Balance 0 F2: These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship.

F2: These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Taysha Gene Therapies, Inc.

Report date May 30, 2025 · Filed June 04, 2025

Section 16 reporting ended · disclosed 2025-06-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,841,704	Reported balance After 2025-05-30 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2025-05-30 · Purchase · Acquired 750,000 · Balance 2,841,704 F1: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	14,723,948.12	Reported balance Holding disclosure · report date 2025-05-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 14,723,948.12 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F3: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Revocable Trust"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	22,000	Reported balance Holding disclosure · report date 2025-05-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 22,000 F4: The shares are held directly by BKB G2 Investments, LLC ("BKB G2"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB G2, and has shared voting and investment power with respect to the shares held by BKB G2.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,013,458.88	Reported balance Holding disclosure · report date 2025-05-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 4,013,458.88 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F5: The shares are held directly by The PBM 2023 Grantor Retained Annuity Trust (the "2023 Annuity Trust"). The Reporting Person is the trustee of the 2023 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2023 Annuity Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,000,000	Reported balance Holding disclosure · report date 2025-05-30 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 4,000,000 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F6: The shares are held directly by The PBM 2025 Grantor Retained Annuity Trust (the "2025 Annuity Trust"). The Reporting Person is the trustee of the 2025 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2025 Annuity Trust.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16.

F3: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Revocable Trust"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust.

F4: The shares are held directly by BKB G2 Investments, LLC ("BKB G2"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB G2, and has shared voting and investment power with respect to the shares held by BKB G2.

F5: The shares are held directly by The PBM 2023 Grantor Retained Annuity Trust (the "2023 Annuity Trust"). The Reporting Person is the trustee of the 2023 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2023 Annuity Trust.

F6: The shares are held directly by The PBM 2025 Grantor Retained Annuity Trust (the "2025 Annuity Trust"). The Reporting Person is the trustee of the 2025 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2025 Annuity Trust.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 28, 2020 Filed Sep 30, 2020 20:37 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	ConversionCommon Stock	2,008,158	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-052459 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,008,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
September 28, 2020 Filed Sep 30, 2020 20:37 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	ConversionCommon Stock	3,275,205	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-052459 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,275,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
September 23, 2020 Filed Sep 25, 2020 21:11 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	GrantStock Option (right to buy) · Derivative	31,000	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001209191-20-052113 · doc4.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2030-09-23 F1 · derivative.exercise_date: The shares subject to the Option vest in 36 equal monthly installments, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
August 20, 2020 Filed Aug 21, 2020 11:44 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	20,000	$9.09	$181,800.00	Disclosure SEC source: 0001209191-20-047865 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,099,394 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.00 to $9.3279 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 344,611 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
August 18, 2020 Filed Aug 19, 2020 12:40 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	10,000	$8.55	$85,500.00	Disclosure SEC source: 0001209191-20-047409 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,481,719 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.305 to $8.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
August 17, 2020 Filed Aug 18, 2020 12:35 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	6,000	$6.92	$41,520.00	Disclosure SEC source: 0001209191-20-047100 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,471,719 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.80 to $6.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
August 14, 2020 Filed Aug 17, 2020 13:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	50,000	$6.51	$325,500.00	Disclosure SEC source: 0001209191-20-046880 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,465,719 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.10 to $6.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
August 13, 2020 Filed Aug 17, 2020 13:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	108,500	$6.41	$695,485.00	Disclosure SEC source: 0001209191-20-046880 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,415,719 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.23 to $6.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
November 12, 2019 Filed Nov 12, 2019 16:38 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	OtherCommon Stock	1,783,226	$27.50	$49,038,715.00	Disclosure SEC source: 0001209191-19-056038 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 F2 · ownership.nature: These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
November 12, 2019 Filed Nov 12, 2019 16:38 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	OtherCommon Stock	12,979,016	$27.50	$356,922,940.00	Disclosure SEC source: 0001209191-19-056038 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
October 10, 2019 Filed Oct 10, 2019 21:03 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	6,900	$15.05	$103,845.00	Disclosure SEC source: 0001209191-19-052936 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,079,394 F5 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $14.74 to $15.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F6 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 324,611 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
October 09, 2019 Filed Oct 10, 2019 21:03 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	8,778	$14.06	$123,418.68	Disclosure SEC source: 0001209191-19-052936 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,072,494 F3 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $13.90 to $14.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 317,711 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
October 08, 2019 Filed Oct 10, 2019 21:03 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	5,208	$14.02	$73,016.16	Disclosure SEC source: 0001209191-19-052936 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,063,716 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $13.98 to $14.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 308,933 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
August 09, 2019 Filed Aug 12, 2019 16:15 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	28,062	$15.87	$445,343.94	Disclosure SEC source: 0001209191-19-045495 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,979,016 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.40 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
March 07, 2019 Filed Mar 8, 2019 08:46 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	68,000	$7.48	$508,640.00	Disclosure SEC source: 0001209191-19-017935 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950,954 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.345 to $7.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · balance_after: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 736,001 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
January 07, 2019 Filed Jan 8, 2019 01:51 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	911	$11.99	$10,922.89	Disclosure SEC source: 0001209191-19-002674 · doc4.xml · nonDerivative · entry 6 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,307,219 F5 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $11.98 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · ownership.direct: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
January 07, 2019 Filed Jan 8, 2019 01:51 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	6,706	$11.55	$77,454.30	Disclosure SEC source: 0001209191-19-002674 · doc4.xml · nonDerivative · entry 5 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,306,308 F3 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.98 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · ownership.direct: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
January 07, 2019 Filed Jan 8, 2019 01:51 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	4,258	$10.41	$44,325.78	Disclosure SEC source: 0001209191-19-002674 · doc4.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,299,602 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $9.87 to $10.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · ownership.direct: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
January 07, 2019 Filed Jan 8, 2019 01:51 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	2,734	$11.99	$32,780.66	Disclosure SEC source: 0001209191-19-002674 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,058,508 F5 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $11.98 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F6 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 303,725 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
January 07, 2019 Filed Jan 8, 2019 01:51 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	20,116	$11.55	$232,339.80	Disclosure SEC source: 0001209191-19-002674 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,055,774 F3 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.98 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 300,991 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
January 07, 2019 Filed Jan 8, 2019 01:51 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	12,775	$10.41	$132,987.75	Disclosure SEC source: 0001209191-19-002674 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,035,658 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $9.87 to $10.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 280,875 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:09 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	6,834	$7.10	$48,521.40	Disclosure SEC source: 0001209191-18-063955 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,882,954 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.07 to $7.27, inclusive. F4 · ownership.direct: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 668,001 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:09 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	121,666	$6.44	$783,529.04	Disclosure SEC source: 0001209191-18-063955 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,876,120 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.04 to $7.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.direct: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 661,167 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
December 20, 2018 Filed Dec 20, 2018 17:28 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	266,631	$6.17	$1,645,113.27	Disclosure SEC source: 0001209191-18-063714 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,754,454 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.03 to $6.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.direct: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 539,501 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
November 13, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	55	$15.60	$858.00	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 10 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,295,344 F10 · price: This transaction was executed in multiple trades at prices ranging from $15.55 to $15.60, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
November 13, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	55	$15.60	$858.00	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 9 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,022,883 F10 · price: This transaction was executed in multiple trades at prices ranging from $15.55 to $15.60, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F11 · ownership.direct: Consists of 7,754,783 shares of common stock held by Mr. Manning and 268,100 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
November 13, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	9,418	$14.94	$140,704.92	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 8 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,295,289 F8 · price: This transaction was executed in multiple trades at prices ranging from $14.50 to $15.36, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
November 13, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	9,418	$14.94	$140,704.92	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 7 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,022,828 F8 · price: This transaction was executed in multiple trades at prices ranging from $14.50 to $15.36, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F9 · ownership.direct: Consists of 7,754,783 shares of common stock held by Mr. Manning and 268,045 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
November 13, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	10,527	$14.08	$148,220.16	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 6 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,285,871 F6 · price: This transaction was executed in multiple trades at prices ranging from $13.50 to $14.47, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
November 13, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	10,527	$14.08	$148,220.16	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 5 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,013,410 F6 · price: This transaction was executed in multiple trades at prices ranging from $13.50 to $14.47, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F7 · ownership.direct: Consists of 7,754,783 shares of common stock held by Mr. Manning and 258,627 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
November 12, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	9,950	$13.96	$138,902.00	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,275,344 F4 · price: This transaction was executed in multiple trades at prices ranging from $13.70 to $14.31, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
November 12, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	9,950	$13.96	$138,902.00	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,002,883 F4 · price: This transaction was executed in multiple trades at prices ranging from $13.70 to $14.31, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F5 · ownership.direct: Consists of 7,754,783 shares of common stock held by Mr. Manning and 248,100 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
November 12, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	5,150	$13.17	$67,825.50	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,265,394 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.615 to $13.60, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
November 12, 2018 Filed Nov 14, 2018 21:30 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	5,150	$13.17	$67,825.50	Disclosure SEC source: 0001209191-18-058536 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,992,933 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.615 to $13.60, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.direct: Consists of 7,754,783 shares of common stock held by Mr. Manning and 238,150 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
August 10, 2018 Filed Aug 14, 2018 20:39 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	33,000	$15.08	$497,640.00	Disclosure SEC source: 0001209191-18-046616 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,787,783 F1 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.30, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.direct: Consists of 7,754,783 shares of common stock held by Mr. Manning and 33,000 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
June 19, 2018 Filed Jun 19, 2018 20:46 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	ConversionSeries A Convertible Preferred Stock · Derivative	256,634	$0.00	$0.00	Disclosure SEC source: 0001209191-18-038593 · doc4.xml · derivative · entry 6 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 256,634 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F3 · ownership.nature: The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is President and CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI. Read SEC document
June 19, 2018 Filed Jun 19, 2018 20:46 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	ConversionSeries A Convertible Preferred Stock · Derivative	1,132,900	$0.00	$0.00	Disclosure SEC source: 0001209191-18-038593 · doc4.xml · derivative · entry 5 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,132,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
June 19, 2018 Filed Jun 19, 2018 20:46 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	ConversionSeries A Convertible Preferred Stock · Derivative	7,754,783	$0.00	$0.00	Disclosure SEC source: 0001209191-18-038593 · doc4.xml · derivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,754,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document
June 19, 2018 Filed Jun 19, 2018 20:46 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	ConversionCommon Stock	256,634	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-038593 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 256,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F3 · ownership.nature: The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is President and CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI. Read SEC document
June 19, 2018 Filed Jun 19, 2018 20:46 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	ConversionCommon Stock	1,132,900	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-038593 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,160,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
June 19, 2018 Filed Jun 19, 2018 20:46 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	ConversionCommon Stock	7,754,783	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-038593 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,754,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document
June 19, 2018 Filed Aug 15, 2018 20:44 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	100,000	$15.00	$1,500,000.00	Disclosure SEC source: 0001209191-18-046821 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,260,244 F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. Read SEC document
June 19, 2018 Filed Aug 15, 2018 20:44 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	200,000	$15.00	$3,000,000.00	Disclosure SEC source: 0001209191-18-046821 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,987,783 F1 · balance_after: This represent the total number of shares owned by the Reporting Person including the shares acquired on August 10, 2018. F2 · ownership.direct: Consists of 7,754,783 shares of common stock held by Mr. Manning and 233,000 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
June 07, 2018 Filed Jun 8, 2018 08:17 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	3,400	$28.03	$95,302.00	Disclosure SEC source: 0001209191-18-036564 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,487,823 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.00 to $28.07, inclusive. F6 · ownership.direct: Consists of (i) 12,214,953 shares held directly by Manning, and (ii) 272,870 shares held by Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
June 07, 2018 Filed Jun 8, 2018 08:17 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	6,600	$27.52	$181,632.00	Disclosure SEC source: 0001209191-18-036564 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,484,423 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.99 to $27.915, inclusive. F4 · ownership.direct: Consists of (i) 12,214,953 shares held directly by Manning, and (ii) 269,470 shares held by Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
June 06, 2018 Filed Jun 8, 2018 08:17 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	17,000	$28.85	$490,450.00	Disclosure SEC source: 0001209191-18-036564 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,477,823 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.47 to $29.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (3) and (5) to this Form 4. F2 · ownership.direct: Consists of (i) 12,214,953 shares held directly by Manning, and (ii) 262,870 shares held by Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
June 05, 2018 Filed Jun 6, 2018 08:03 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	53,020	$26.93	$1,427,828.60	Disclosure SEC source: 0001209191-18-035971 · doc4.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,460,823 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.665 to $27.27, inclusive. F8 · ownership.direct: Consists of (i) 12,334,953 shares held directly by Manning, and (ii) 125,870 shares held by Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
June 05, 2018 Filed Jun 6, 2018 08:03 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	46,980	$26.04	$1,223,359.20	Disclosure SEC source: 0001209191-18-035971 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,407,803 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.65 to $26.60, inclusive. F6 · ownership.direct: Consists of (i) 12,281,933 shares held directly by Manning, and (ii) 125,870 shares held by Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
June 04, 2018 Filed Jun 6, 2018 08:03 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	11,800	$24.75	$292,050.00	Disclosure SEC source: 0001209191-18-035971 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,360,823 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.54 to $24.83, inclusive. F4 · ownership.direct: Consists of (i) 12,234,953 shares held directly by Manning, and (ii) 125,870 shares held by Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document
June 04, 2018 Filed Jun 6, 2018 08:03 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	PurchaseCommon Stock	8,200	$24.02	$196,964.00	Disclosure SEC source: 0001209191-18-035971 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,349,023 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.535 to $24.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (5) and (7) to this Form 4. F2 · ownership.direct: Consists of (i) 12,223,153 shares held directly by Manning, and (ii) 125,870 shares held by Manning together with his spouse as Joint Tenants with Right of Survivorship. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.